Antiviral traditional Chinese medicine awarded U.S., Japan patents

A pharmacist weighs ingredients to produce traditional Chinese medicine (TCM) decoctions at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine in north China's Tianjin, Jan. 12, 2022. (Xinhua/Li Ran)

BEIJING, Feb. 19 (Xinhua) -- An antiviral traditional Chinese medicine (TCM) composition has been awarded patents by Japan and the United States successively, said a Chinese pharmaceutical company.

The medicine is a composition of effective components extracted from TCM raw materials, and has obvious broad-spectrum antiviral effects, said Jia Hongzhang, founder of the Beijing pharmaceutical company Hongtianli.

The composition has been proved effective against influenza A virus, HIN1, and Zika virus among others by researches from home and abroad.

The research of the composition's effect mechanism against COVID-19 has also been carried out recently.

The patent of the medicine composition was registered by the Japan Patent Office on Jan. 13, 2022, and it was awarded the United States Patent on Feb. 1, 2022, according to Jia.

Editor: Yang Yifan
Today’s Recommendations

Infographics | Highlights of China-Africa trade cooperation

Since the 2018 Forum on China-Africa Cooperation in Beijing, China and Africa have enhanced their solidarity and mutual trust, especially during the COVID-19 pandemic. Here are some statistics from the trade cooperation between China and Africa. These figures demonstrate the confidence of Chinese enterprises in Africa's future and the prospects of the African market.【detailed】

Economic Watch: Road, trade and exchange, China and ASEAN countries forge closer community

A handful of seashells are on display in a museum in southwest China's border province of Yunnan, recording the country's past history of international communication.【detailed】